A Phase 4 interventional study of Pradaxa, dabigatran etexilate in Atrial Fibrillation, sponsored by Boehringer Ingelheim. Completed at 26 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-30.
Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies testing dabigatran in Atrial Fibrillation — none open to participants now, 1 under way, none of them phase 3. Dabigatran · Atrial Fibrillation.
Among the 35 studies testing dabigatran in Atrial Fibrillation, this one is the 25th largest by enrollment, is one of 4 that started in 2013, is one of 22 in phase 4, and was the 12th registered.
4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.
Browse Atrial Fibrillation studies →None of the 35 studies testing dabigatran in Atrial Fibrillation is open now. The open studies under Atrial Fibrillation, anywhere →
Dabigatran: first FDA approval 2010 (PRADAXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 7 · Phase 4 22
First in 2003; this study’s year is marked. 4 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 63 is below the median of 150 across 2,477 interventional studies indexed under Atrial Fibrillation.
Median enrollment 174 across the 35 interventional studies. Of the 23 that completed or were terminated, 11 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 35 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
45 studies in Atrial Fibrillation by Boehringer Ingelheim: none open now, none under way, none of them phase 3. Of 45 finished, 44 (98%) have results posted.
Among the 45 studies in Atrial Fibrillation by Boehringer Ingelheim, this one is one of 5 that started in 2013, is one of 3 in phase 4, and was the 15th registered.
Boehringer Ingelheim’s Atrial Fibrillation studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 35 studies testing dabigatran in Atrial Fibrillation, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 45 in Atrial Fibrillation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this study is to assess dabigatran pharmacokinetics in NVAF subjects with severe renal impairment defined as creatinine clearance between 15 and 30 mL/min calculated by Cockcroft-Gault formula.
The dabigatran etexilate dose of 75 mg BID was approved by the FDA for NVAF patients with severe renal impairment (CrCl 15-30 mL/min) , based on pharmacokinetic modeling and simulation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
75mg BID by oral
Drug: Pradaxa, dabigatran etexilate
75mg BID by oral
Pre-dose Concentration of the Analyte in Plasma at Steady State Immediately Before Administration of the Next Dose
Pre-dose concentration of the analyte in plasma at steady state immediately before administration of the next dose (Cpre,ss) taken at approximately 12 hours after the last dose (trough).
Time frame: Immediately before the last drug administration, on day 8
Concentration of Analyte in Plasma at Steady State at 2 Hours After Administration of the Last Dose
Concentration of analyte in plasma at steady state at 2 hours after administration of the last dose (C2,ss)
Time frame: 2 hours after the last drug administration, on day 8
| Milestone | Dabigatran Etexilate |
|---|---|
| Started | 60 |
| Completed | 59 |
| Not completed | 1 |
| Withdrew: Died in post treatment phase | 1 |
Pre-dose concentration of the analyte in plasma at steady state immediately before administration of the next dose (Cpre,ss) taken at approximately 12 hours after the last dose (trough).
| ng/mL | Dabigatran Etexilate |
|---|---|
| Pre-dose Concentration of the Analyte in Plasma at Steady State Immediately Before Administration of the Next Dose | 155 ± 76.9 |
Concentration of analyte in plasma at steady state at 2 hours after administration of the last dose (C2,ss)
| ng/mL | Dabigatran Etexilate |
|---|---|
| Concentration of Analyte in Plasma at Steady State at 2 Hours After Administration of the Last Dose | 202 ± 70.6 |
Collected over From first drug administration until 3 days after last drug administration, up to 18 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dabigatran Etexilate | — | 2/60 (3.3%) | 0/60 (0%) |
| Event | Dabigatran Etexilate |
|---|---|
| Acute myocardial infarctionCardiac disorders | 1/60 |
| HyperkalaemiaMetabolism and nutrition disorders | 1/60 |
Treated set (TS) which included all enrolled patients who were eligible to enter the trial, who were dispensed trial medication and were documented to have taken at least one dose of trial drug.
| Age, Continuous(Years) | Dabigatran Etexilate |
|---|---|
| Mean | 83.35 ± 7.55 |
| Sex: Female, Male(Participants) | Dabigatran Etexilate |
|---|---|
| Female | 36 |
| Male | 24 |
The record gives a start of Jul 2013, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2016, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dabigatran